|
|
|||||||||||||||
|
|
Polyarthropathy associated with human parvovirus B19 (B19) is
usually transient, but often resembles rheumatoid arthritis (RA).1-3 However, B19 DNA screened by polymerase chain
reaction (PCR) may be positive not only in autoimmune diseases, but
also in non-arthropathy.4 To study whether or not RA
occurs after acute B19 infection, we conducted a prospective study of
patients with acute onset polyarthritis. Sixty seven cases showing
acute inflammatory polyarthritis from January 1990 to June 1990 were examined and followed up for six years. Among them, 12 (9 female and 3 male) exhibited IgM anti-B19 antibodies.5 PCR, followed by
a Southern blot analysis6 also showed the presence of B19 DNA in all 12 cases with IgM anti-B19 antibodies, but did not in the
remainder. Initially, rheumatoid factor (RF) was negative in all B19
positive cases except one, but became positive in four, two to four
months after the infection (table 1). Among RF positive cases, three
(MI, RM, and TY) developed active polyarthritis with destructive
changes in the joints including fingers, wrists or elbows, and
rheumatoid nodules. These patients were diagnosed as typical RA
fulfilling the 1987 American College of Rheumatology (ACR) criteria for
the diagnosis of RA7 as shown in table 2. No cases in the
B19 negative group met the ACR criteria for RA during six years of
follow up.
|
|
Figure 1 shows that B19 DNA was no longer detected in blood
samples from the patients MI, RM, and TY four months after the initial
episodes. It was, however, positive in bone marrow and synovial tissue.
Both in situ hybridisation (ISH) and immunofluorescence (IF)
study8 9 also revealed the presence of B19 DNA/RNA as well as VP-1 antigen in mononuclear cells of bone marrow samples (fig
2). Examination of peripheral mononu-clear cells by the stimulation with B19 antigen, showed significantly higher proliferative responses to recombinant VP-1 in patients MI, RM, and TY compared with others (p<0.002).
|
|
Clinically, three patients with RA were in an active stage and, therefore, treated with a high dose (20 g/day) of gammaglobulin for 10 days (fig 1) after a variety of anti-rheumatic drugs including gold, D-penicillamine or methotrexate became ineffective. The treatment caused a reduction in multiple joint pain and swelling, and a decrease in the C reactive protein value (from 0.8 to 0.3 for patient MI and from 3.6 to 2.0 for patient RM). The number of VP-1 positive cells in bone marrow markedly decreased after the treatment (from 3.6% or 2.6%, to undetectable values or 0.5% in MI and RM respectively).
The prevalence of IgM anti-B19 antibodies in this area was below 0.1% at the time of the study, and so far we have not obtained the evidence of B19 DNA/RNA and VP-1 antigens in the bone marrow samples from patients with haematological diseases, when screened by ISH and IF. The patients in this study developed RA with destructive changes in the joints after acute B19 infection, and had the evidence of persistent activation of B19 in vivo, as demonstrated in a subject with recurrent episodes of B19 infection.10 The decrease of B19 positive cells in bone marrow and their clinical improvement subsequent to intravenous immunoglobulin therapy also supports our view of a relation between B19 infection and polyarthritis, as indicated in the case with a recovery from B19 associated pure red cell aplasia after immunoglobulin therapy.11 Furthermore, the transfection of NS-1 gene of B19 has been shown to induce an increased IL6 production in vitro.12 Our results indicate that B19 should be investigated in association with the aetiopathogenesis of RA.
CHIHIRO MURAI, YASUHIKO MUNAKATA, YUICHI TAKAHASHI, TOMONORI ISHII, SHINOBU SHIBATA, TAI MURYOI, TADAO FUNATO, MASATAKA NAKAMURA, KAZUO SUGAMURA, TAKESHI SASAKI
The Second Department of Internal Medicine, Bacteriology,
Clinical and Laboratory Medicine, Tohoku University School of Medicine,
Sendai, 980 Japan
Correspondence to: Dr T Sasaki. References
1. | White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Barcon PA. Human parvovirus arthropathy. Lancet 1985;i:419-421. |
2. | Reid DM, Reid TMS, Brown T, Rennie JA, Eastmond CJ. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1985;i:422-424. |
3. | Lefrere JJ, Meyer O, Menkes CJ, Beaulieu MJ, Courouce AM. Human parvovirus and rheumatoid arthritis. Lancet 1985;i:982. |
4. | Soderlund M, von Essen R, Haapasaari J, Kijstala U, Kiviluoto O, Hedman K, et al. Persistence of parvovirus B19 DNA in synovial membranes of youg patients with and without chronic arthropathy. Lancet 1997;349:1063-1065[Medline]. |
5. | Yaegashi N, Okamura K, Yajima A, Murai C, Sugamura K. The frequency of human parvovirus B19 infection in nonimmune hydrops fetus. J Perinat Med 1994;22:159-162[Medline]. |
6. |
Takahashi Y,
Murai C,
Shibata S,
Munakata Y,
Ishii T,
Ishii K,
et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis.
Proc Natl Acad Sci
1998;95:8227-8232 |
7. | Amett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324[Medline]. |
8. |
Yaegashi N,
Shiraishi H,
Takeshita T,
Wakamura M,
Yajima A,
Sugamura K. Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver.
J Virol
1989;63:2422-2425 |
9. | Miyamasu M, Hirai K, Takahashi Y, Iida M, Ohtoshi T, Takaishi T, et al. Chemotactic ago-nists induce cytokine generation in eosinophilles. J Immunol 1995;154:1339-1349[Abstract]. |
10. | Sasaki T, Murai C, Muryoi T, Takahashi Y, Munakata Y, Sugamura K, et al. Persistent infection of human parvovirus B19 in a normal subject. Lancet 1995;346:851[Medline]. |
11. | Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 year's duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-523[Medline]. |
12. | Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka O, et al. A cytotoxic nonstructural protein, NSI, of human parvovirus B19 induces activaton of interleukin-6 gene expression. J Virol 1996;70:8485-8491[Abstract]. |
This article has been cited by other articles: (Search Google Scholar for Other Citing Articles)
|
|
V. Kasprowicz, A. Isa, T. Tolfvenstam, K. Jeffery, P. Bowness, and P. Klenerman Tracking of Peptide-Specific CD4+ T-Cell Responses after an Acute Resolving Viral Infection: a Study of Parvovirus B19 J. Virol., November 15, 2006; 80(22): 11209 - 11217. [Abstract] [Full Text] [PDF] |
|||
|
|
Y. Munakata, T. Saito-Ito, K. Kumura-Ishii, J. Huang, T. Kodera, T. Ishii, Y. Hirabayashi, Y. Koyanagi, and T. Sasaki Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection Blood, November 15, 2005; 106(10): 3449 - 3456. [Abstract] [Full Text] [PDF] |
|||
|
|
H. Yoshitomi, N. Sakaguchi, K. Kobayashi, G. D. Brown, T. Tagami, T. Sakihama, K. Hirota, S. Tanaka, T. Nomura, I. Miki, S. Gordon, S. Akira, T. Nakamura, and S. Sakaguchi A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice J. Exp. Med., March 21, 2005; 201(6): 949 - 960. [Abstract] [Full Text] [PDF] |
|||
|
|
N. Takasawa, Y. Munakata, K. K. Ishii, Y. Takahashi, M. Takahashi, Y. Fu, T. Ishii, H. Fujii, T. Saito, H. Takano, T. Noda, M. Suzuki, M. Nose, S. Zolla-Patzner, and T. Sasaki Human Parvovirus B19 Transgenic Mice Become Susceptible to Polyarthritis J. Immunol., October 1, 2004; 173(7): 4675 - 4683. [Abstract] [Full Text] [PDF] |
|||
|
|
Y. Fu, K. K. Ishii, Y. Munakata, T. Saitoh, M. Kaku, and T. Sasaki Regulation of Tumor Necrosis Factor Alpha Promoter by Human Parvovirus B19 NS1 through Activation of AP-1 and AP-2 J. Virol., May 3, 2002; 76(11): 5395 - 5403. [Abstract] [Full Text] [PDF] |
|||
|
|
J. R Kerr Pathogenesis of human parvovirus B19 in rheumatic disease Ann Rheum Dis, September 1, 2000; 59(9): 672 - 683. [Full Text] |
gipoco.com
is neither affiliated with the authors of this page or responsible
for its contents. This is a safe-cache copy of the original web site.
gipoco.com
is neither affiliated with the authors of this page nor responsible
for its contents. This is a safe-cache copy of the original web site.
|